These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2567112)

  • 1. Preclinical pharmacologic properties of dilevalol, an antihypertensive agent possessing selective beta 2 agonist-mediated vasodilation and beta antagonism.
    Sybertz EJ; Watkins RW
    Am J Cardiol; 1989 Jun; 63(19):3I-6I. PubMed ID: 2567112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of beta 2-receptor stimulation in the peripheral vascular actions of the antihypertensive dilevalol.
    Watkins RW; Sybertz EJ; Cook J; Pula K; Cedeno K; Tedesco RP; McLeod R
    Arch Int Pharmacodyn Ther; 1989; 302():158-73. PubMed ID: 2576892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dilevalol: a selective beta-2 adrenergic agonist vasodilator with beta adrenergic blocking activity.
    Wallin JD; Frishman WH
    J Clin Pharmacol; 1989 Dec; 29(12):1057-68. PubMed ID: 2693499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic effects of beta-blocking compounds possessing vasodilating activity: a review of labetalol, prizidilol, and dilevalol.
    Lund-Johansen P
    J Cardiovasc Pharmacol; 1988; 11 Suppl 2():S12-7. PubMed ID: 2464093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dose dependency of the alpha-adrenoceptor antagonist and beta-adrenoceptor partial agonist activity of dilevalol and labetalol in man.
    Tham TC; McKaigue JP; Guy S; Shanks RG; Riddell JG
    Br J Clin Pharmacol; 1993 Sep; 36(3):251-6. PubMed ID: 9114912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dilevalol: an overview of its clinical pharmacology and therapeutic use in hypertension.
    Lalonde RL; Tenero DM; Kazierad DJ
    Pharmacotherapy; 1990; 10(1):15-28. PubMed ID: 2179899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actions of dilevalol on adrenoceptors.
    Louis WJ; Drummer OH; Tung LH
    J Cardiovasc Pharmacol; 1988; 11 Suppl 2():S5-11. PubMed ID: 2464095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrinsic beta-sympathomimetic activity of dilevalol, R, R-isomer of labetalol.
    Matsunaga K; Nakamura K; Ueda M
    J Pharmacobiodyn; 1985 Sep; 8(9):785-7. PubMed ID: 2868089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the antihypertensive dilevalol on large artery compliance in anesthetized dogs.
    Watkins RW; Sybertz EJ; Antonellis A; Pula K; Rivelli M
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S58-63. PubMed ID: 2454369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacodynamics of dilevalol.
    Riddell JG
    J Hum Hypertens; 1990 Jun; 4 Suppl 2():39-44. PubMed ID: 2370642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of labetalol in experimental animals.
    Baum T; Sybertz EJ
    Am J Med; 1983 Oct; 75(4A):15-23. PubMed ID: 6314811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-blocking agents with vasodilating action.
    Prichard BN
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S1-4. PubMed ID: 1378133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dilevalol on forearm circulation in essential hypertension.
    Giannattasio C; Cleroux J; Seravalle G; Grassi G; Mancia G; Zanchetti A
    Am J Cardiol; 1989 Jun; 63(19):21I-24I. PubMed ID: 2567111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive effect of dilevalol is directly related to dose and plasma concentrations.
    Given BD; Perentesis G; Christopher JD; Herron J; Patrick JE; Kramer WG; Affrime MB
    Am J Cardiol; 1989 Jun; 63(19):12I-16I. PubMed ID: 2729123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dilevalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension.
    Chrisp P; Goa KL
    Drugs; 1990 Feb; 39(2):234-63. PubMed ID: 2184002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular electrophysiology and beta-adrenergic-blocking activity of dilevalol, the R,R-isomer of labetalol, on isolated canine cardiac tissues.
    Zaim S; Dangman KH
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):496-501. PubMed ID: 2476632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.
    Brittain RT; Levy GP
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):681-4. PubMed ID: 10948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect.
    Lund-Johansen P; Omvik P
    Cardiovasc Drugs Ther; 1991 Jun; 5(3):605-15. PubMed ID: 1678963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive and hemodynamic actions of SCH 19927, the R,R-isomer and labetalol.
    Baum T; Watkins RW; Sybertz EJ; Vemulapalli S; Pula KK; Eynon E; Nelson S; Vliet GV; Glennon J; Moran RM
    J Pharmacol Exp Ther; 1981 Aug; 218(2):444-52. PubMed ID: 7252843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of dilevalol and propranolol on systemic and regional haemodynamics in healthy volunteers at rest and during exercise.
    Bellissant E; Annane D; Thuillez C; Giudicelli JF
    Eur J Clin Pharmacol; 1994; 47(1):39-47. PubMed ID: 7988622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.